Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Memorial Sloan Kettering Cancer Center · University of North Carolina at Chapel Hill · +6 more institutions
Abstract
Between June 2004 and April 2006, 602 patients were enrolled onto the study and 535 were treated. Median overall survival was 5.8 months for gemcitabine/bevacizumab and 5.9 months for gemcitabine/placebo (P = .95). Median progression-free survival was 3.8 and 2.9 months, respectively (P = .07). Overall response rates were 13% and 10%, respectively. Patients with a performance status of 0, 1, and 2 survived a median of 7.9, 4.8, and 2.4 months, respectively. The only statistically significant differences in grades 3 and 4 toxicity occurred for hypertension (10% v 3%; P or = 3 was equivalent in both arms (14% and 15%, respectively).
The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients.
Citation impact
- FWCI
- 38.50
- Percentile
- 100%
- References
- 38
Authors
15- HLHedy L. KindlerCorresponding
Memorial Sloan Kettering Cancer Center
- DNDonna Niedzwiecki
University of North Carolina at Chapel Hill, Christiana Care Health System, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Chicago, Dana-Farber Cancer Institute, Duke Medical Center, Cancer Research Center
- DHDonna Hollis
University of North Carolina at Chapel Hill, Christiana Care Health System, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Chicago, Dana-Farber Cancer Institute, Duke Medical Center, Cancer Research Center
- SSSusan Sutherland
University of North Carolina at Chapel Hill, Christiana Care Health System, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Chicago, Dana-Farber Cancer Institute, Duke Medical Center, Cancer Research Center
- DSDeborah Schrag
University of North Carolina at Chapel Hill, Christiana Care Health System, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Chicago, Dana-Farber Cancer Institute, Duke Medical Center, Cancer Research Center
Topics & keywords
- Gemcitabine
- Medicine
- Bevacizumab
- Internal medicine
- Pancreatic cancer
- Placebo
- Clinical endpoint
- Gastroenterology
- Good health and well-being